|
|
Volumn 11, Issue 11, 2010, Pages 1020-1021
|
|
Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPHIREGULIN;
B RAF KINASE;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
EPIREGULIN;
K RAS PROTEIN;
MESSENGER RNA;
ONCOPROTEIN;
PANITUMUMAB;
PROTEIN NRAS;
PROTEIN PIK3CA;
UNCLASSIFIED DRUG;
CLINICAL PRACTICE;
CLINICAL TRIAL;
COLORECTAL CANCER;
COST BENEFIT ANALYSIS;
DRUG EFFICACY;
EXON;
GENE DOSAGE;
GENE EXPRESSION;
GENE EXPRESSION PROFILING;
GENE FUNCTION;
GENE MUTATION;
HUMAN;
LETTER;
PRIORITY JOURNAL;
PROTEIN TARGETING;
ANTINEOPLASTIC AGENTS;
COLORECTAL NEOPLASMS;
DRUG RESISTANCE, NEOPLASM;
GENES, RAS;
GENETIC TESTING;
HUMANS;
INDIVIDUALIZED MEDICINE;
MUTATION;
PATIENT SELECTION;
PHOSPHATIDYLINOSITOL 3-KINASES;
PROTEIN KINASE INHIBITORS;
PROTO-ONCOGENE PROTEINS;
PROTO-ONCOGENE PROTEINS B-RAF;
RAS PROTEINS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 78049524827
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(10)70211-4 Document Type: Letter |
|
Times cited : (1)
|
|
References (5)
|
